Inventor · disambiguated record
Abraham Scaria
Also filed as: SCARIA ABRAHAM · SCARIA ABRAHAM VAMATTATHIL
33 granted patents·18 pending applications·251 citations·filing 1997–2025
96Inventor score
Top patents by PatentIndex Score
51 records- 0195US7045508B2Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsGENZYME CORP·Filed 2002·Granted May 16, 2006·35 cites·12 claims
- 0292US7928072B2Multimeric constructsGENZYME CORP·Filed 2007·Granted Apr 19, 2011·21 cites·35 claims
- 0392US6020191AAdenoviral vectors capable of facilitating increased persistence of transgene expressionGENZYME CORP·Filed 1997·Granted Feb 1, 2000·127 cites·3 claims
- 0491US12122998B2Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)CRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 22, 2024·2 cites·22 claims
- 0589US11072792B2Materials and methods for treatment of usher syndrome type 2ACRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 27, 2021·2 cites·16 claims
- 0689US10982228B2AAV vectors for retinal and CNS gene therapyGENZYME CORP·Filed 2015·Granted Apr 20, 2021·4 cites·36 claims
- 0789US10183983B2Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2017·Granted Jan 22, 2019·7 cites·8 claims
- 0888US12241078B2AAV vectors for retinal and CNS gene therapyGENZYME CORP·Filed 2021·Granted Mar 4, 2025·1 cites·37 claims
- 0988US11118177B2Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)CRISPR THERAPEUTICS AG·Filed 2020·Granted Sep 14, 2021·3 cites·2 claims
- 1088US7615537B2Methods for treating blood coagulation disordersGENZYME CORP·Filed 2001·Granted Nov 10, 2009·19 cites·49 claims
- 1188US7307068B2Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsGENZYME CORP·Filed 2005·Granted Dec 11, 2007·3 cites·5 claims
- 1287US10662425B2Materials and methods for treatment of autosomal dominant retinitis pigmentosaCRISPR THERAPEUTICS AG·Filed 2018·Granted May 26, 2020·3 cites·30 claims
- 1387US9637534B2Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2014·Granted May 2, 2017·8 cites·10 claims
- 1486US12215316B2Materials and methods for treatment of usher syndrome type 2ACRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 4, 2025·1 cites·7 claims
- 1580US2025101439A1Materials and methods for controlling gene editingCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1679US10309585B2Light emitting deviceSIGNIFY HOLDING BV·Filed 2014·Granted Jun 4, 2019·4 cites·13 claims
- 1779US2025122497A1Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)CRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1878US8658602B2Multimeric constructsSCARIA ABRAHAM·Filed 2011·Granted Feb 25, 2014·4 cites·28 claims
- 1976US2025283088A1Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2025·Application pending·0 cites
- 2075US11604321B2Light generating system comprising an elongated luminescent bodySIGNIFY HOLDING BV·Filed 2019·Granted Mar 14, 2023·2 cites·15 claims
- 2174US10640771B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2014·Granted May 5, 2020·1 cites·16 claims
- 2272US9815892B2Multimeric constructsGENZYME CORP·Filed 2014·Granted Nov 14, 2017·1 cites·5 claims
- 2372US2022064262A1Fusion proteins comprising pdgf and vegf binding portions and methods of using thereofGENZYME CORP·Filed 2021·Application pending·0 cites
- 2471US12483047B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2022·Granted Nov 25, 2025·0 cites·22 claims
- 2571US7014848B1Enhanced anti-tumor immunityGENZYME CORP·Filed 2000·Granted Mar 21, 2006·2 cites·12 claims
- 2671US2025320522A1Aav vectors for retinal and cns gene therapyGENZYME CORP·Filed 2025·Application pending·0 cites
- 2771US2008096808A1Use of rapamycin to inhibit response and induce tolerance to gene therapy vector and encoded transgene productsSCARIA ABRAHAM·Filed 2007·Application pending·0 cites
- 2869US2024197837A1Gene editing of deep intronic mutationsGENZYME CORP·Filed 2023·Application pending·0 cites
- 2967US12344842B2Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2020·Granted Jul 1, 2025·0 cites·16 claims
- 3067US12173290B2Materials and methods for controlling gene editingCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 24, 2024·0 cites·28 claims
- 3167US11084864B2Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereofGENZYME CORP·Filed 2018·Granted Aug 10, 2021·0 cites·21 claims
- 3265US8758761B2Combination therapies for treating type 1 diabetesATKINSON MARK A·Filed 2008·Granted Jun 24, 2014·1 cites·16 claims
- 3364US2022340883A1USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTUREGENZYME CORP·Filed 2022·Application pending·0 cites
- 3463US11299715B2Use of iNOS inhibitors to increase viral yield in cultureGENZYME CORP·Filed 2014·Granted Apr 12, 2022·0 cites·9 claims
- 3561US12247201B2Materials and methods for treatment of autosomal dominant retinitis pigmentosaCRISPR THERAPEUTICS AG·Filed 2020·Granted Mar 11, 2025·0 cites·30 claims
- 3661US2011034539A1Methods for treating blood coagulation disordersWADSWORTH SAMUEL·Filed 2009·Application pending·0 cites
- 3760US10995328B2Materials and methods for treatment of autosomal dominant cone-rod dystrophyCRISPR THERAPEUTICS AG·Filed 2020·Granted May 4, 2021·0 cites·16 claims
- 3859US2022081680A1Materials and methods for treatment of autosomal dominant cone-rod dystrophyCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 3958US2018155417A1Multimeric constructsGENZYME CORP·Filed 2017·Application pending·0 cites
- 4058US2002014242A1Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsFiled 2001·Application pending·0 cites
- 4155US2010196401A1Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsGENZYME CORP·Filed 2010·Application pending·0 cites
- 4253US2002019361A1Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene productsFiled 2001·Application pending·0 cites
- 4348US11896651B2Gene editing of deep intronic mutationsGENZYME CORP·Filed 2016·Granted Feb 13, 2024·0 cites·6 claims
- 4444US10822391B2Fusion proteins and methods for inhibiting IL-17 pathwaysSCARIA ABRAHAM·Filed 2010·Granted Nov 3, 2020·0 cites·1 claims
- 4543US10480733B2Flame simulating light-emitting devices and related methodsSIGNIFY HOLDING BV·Filed 2015·Granted Nov 19, 2019·0 cites·19 claims
- 4643US2004023389A1Adenoviral vectors having nucleic acids encoding immunomodulatory moleculesFiled 2002·Application pending·0 cites
- 4741US10821193B2Adeno-associated viral vectors for treating myocilin (MYOC) glaucomaGENZYME CORP·Filed 2015·Granted Nov 3, 2020·0 cites·61 claims
- 4841US2017007719A1Compositions and methods for treating and preventing macular degenerationGENZYME CORP·Filed 2015·Application pending·0 cites
- 4936US2009162345A1Materials and Methods for Reversing Type-1 DiabetesATKINSON MARK A·Filed 2006·Application pending·0 cites
- 5035US2017321867A1Luminaire, luminaire configuration method, computer program product, computing device and lighting systemPHILIPS LIGHTING HOLDING BV·Filed 2015·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →